Last reviewed · How we verify
Second-line Antidepressants
Second-line antidepressants work through various mechanisms including serotonin-norepinephrine reuptake inhibition, noradrenergic activity, or other neurotransmitter modulation to treat depression when first-line agents are ineffective or poorly tolerated.
Second-line antidepressants work through various mechanisms including serotonin-norepinephrine reuptake inhibition, noradrenergic activity, or other neurotransmitter modulation to treat depression when first-line agents are ineffective or poorly tolerated. Used for Major depressive disorder (treatment-resistant or SSRI-intolerant), Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | Second-line Antidepressants |
|---|---|
| Sponsor | Dr. Inge Winter |
| Drug class | Second-line antidepressants (heterogeneous class including SNRIs, tricyclics, atypical agents) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | Phase 3 |
Mechanism of action
Second-line antidepressants encompass multiple drug classes (SNRIs, tricyclic antidepressants, atypical antidepressants, and others) that modulate different neurotransmitter systems beyond selective serotonin reuptake inhibition. These agents are typically used when SSRIs fail due to inadequate efficacy or intolerable side effects, offering alternative mechanisms such as dual serotonin-norepinephrine reuptake inhibition or alpha-2 antagonism to restore mood regulation.
Approved indications
- Major depressive disorder (treatment-resistant or SSRI-intolerant)
- Generalized anxiety disorder
- Panic disorder
- Chronic pain syndromes
Common side effects
- Dry mouth
- Sedation
- Weight gain
- Sexual dysfunction
- Orthostatic hypotension
- Hypertension
- Nausea
Key clinical trials
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Personalized Indications for CBT and Antidepressants in Treating Depression (PHASE4)
- Conus Medullaris Stimulation With 5 Columns Lead Versus Medical Treatment in Refractory Pudendal Neuralgia (NA)
- eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk (PHASE2)
- A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients (NA)
- Microbiotherapy in Characterized Depressive Disorder (PHASE2)
- Subacute Low Back Pain in Active Duty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Second-line Antidepressants CI brief — competitive landscape report
- Second-line Antidepressants updates RSS · CI watch RSS
- Dr. Inge Winter portfolio CI